Advertisement

Molecular Medicine

, Volume 21, Supplement 1, pp S19–S24 | Cite as

25 Years On: A Retrospective on Migration Inhibitory Factor in Tumor Angiogenesis

  • Jason A. Chesney
  • Robert A. Mitchell
Invited Review Article

Abstract

Twenty-five years ago marked the publication of the first report describing a functional contribution by the cytokine, macrophage migration inhibitory factor (MIF), to tumor-associated angiogenesis and growth. Since first appearing, this report has been cited 304 times (as of this writing), underscoring not only the importance of this landmark study but also the importance of MIF in tumor neovascularization. Perhaps more importantly, this first link between MIF and stromal cell-dependent tumor angiogenesis presaged the subsequent identification of MIF in mediating protumorigenic contributions to several solid tumor stromal cell types, including monocytes, macrophages, T lymphocytes, NK cells, fibroblasts, endothelial progenitors and mesenchymal stem cells. This retrospective review will broadly evaluate both past and present literature stemming from this initial publication, with an emphasis on cellular sources, cellular effectors, signal transduction mechanisms and the clinical importance of MIF-dependent tumor vascularization.

Notes

Acknowledgments

This work was supported in part by National Institutes of Health grants NIH CA186661 and NIH CA102285 (both to RA Mitchell).

References

  1. 1.
    Calandra T, Bucala R. (1997) Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit. Rev. Immunol. 17:77–88.CrossRefGoogle Scholar
  2. 2.
    Bacher M, et al. (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. U. S. A. 93:7849–54.CrossRefGoogle Scholar
  3. 3.
    Chesney J, et al. (1999) An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. 5:181–91.CrossRefGoogle Scholar
  4. 4.
    Meyer-Siegler K, Hudson PB. (1996) Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology. 48:448–52.CrossRefGoogle Scholar
  5. 5.
    Takahashi N, et al. (1998) Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol. Med. 4:707–14.CrossRefGoogle Scholar
  6. 6.
    Winner M, Koong AC, Rendon BE, Zundel W, Mitchell RA. (2007) Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res. 67:186–93.CrossRefGoogle Scholar
  7. 7.
    Meyer-Siegler K, Fattor RA, Hudson PB. (1998) Expression S24 of macrophage migration inhibitory factor in the human prostate. Diagn. Mol. Pathol. 7:44–50.CrossRefGoogle Scholar
  8. 8.
    Bando H, et al. (2002) Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn. J. Cancer Res. 93:389–96.CrossRefGoogle Scholar
  9. 9.
    Markert JM, et al. (2001) Differential gene expression profiling in human brain tumors. Physiol. Genomics. 5:21–33.CrossRefGoogle Scholar
  10. 10.
    Shimizu T, et al. (1999) High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem. Biophys. Res. Commun. 264:751–8.CrossRefGoogle Scholar
  11. 11.
    Kamimura A, et al. (2000) Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocar-cinoma of the lung. Cancer. 89:334–41.CrossRefGoogle Scholar
  12. 12.
    David JR. (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. U. S. A. 56:72–7.CrossRefGoogle Scholar
  13. 13.
    Bloom BR, Bennett B. (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 153:80–2.CrossRefGoogle Scholar
  14. 14.
    White ES, Strom SR, Wys NL, Arenberg DA. (2001) Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J. Immunol. 166:7549–55.CrossRefGoogle Scholar
  15. 15.
    Yaddanapudi K, et al. (2013) Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J. Immunol. 190:2984–93.CrossRefGoogle Scholar
  16. 16.
    Rendon BE, et al. (2007) Regulation of human lung adenocarcinoma cell migration and invasion by MIF. J. Biol. Chem. 282:29910–8.CrossRefGoogle Scholar
  17. 17.
    Coleman AM, et al. (2008) Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, D-dopachrome tautomerase. J. Immunol. 181:2330–7.CrossRefGoogle Scholar
  18. 18.
    Winner M, et al. (2008) A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res. 68:7253–7.CrossRefGoogle Scholar
  19. 19.
    Brock SE, Rendon BE, Yaddanapudi K, Mitchell RA. (2012) Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas. J. Biol. Chem. 287:37917–25.CrossRefGoogle Scholar
  20. 20.
    Brock SE, Rendon BE, Xin D, Yaddanapudi K, Mitchell RA. (2014) MIF family members cooperatively inhibit p53 expression and activity. PLoS One 9:e99795.CrossRefGoogle Scholar
  21. 21.
    Wang X, et al. (2012) MIF produced by bone marrow-derived macrophages contributes to teratoma progression after embryonic stem cell transplantation. Cancer Res. 72:2867–78.CrossRefGoogle Scholar
  22. 22.
    Girard E, Strathdee C, Trueblood E, Queva C. (2012) Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model. Br. J. Cancer. 107:1498–505.CrossRefGoogle Scholar
  23. 23.
    Tarnowski M, et al. (2010) Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts. Mol. Cancer Res. 8:1328–43.CrossRefGoogle Scholar
  24. 24.
    Schwartz V, et al. (2012) Role for CD74 and CXCR4 in clathrin-dependent endocytosis of the cytokine MIF. Eur. J. Cell Biol. 91:435–49.CrossRefGoogle Scholar
  25. 25.
    Koch N, Moldenhauer G, Hofmann WJ, Moller P. (1991) Rapid intracellular pathway gives rise to cell surface expression of the MHC class II-associated invariant chain (CD74). J. Immunol. 147:2643–51.PubMedGoogle Scholar
  26. 26.
    Magi B, et al. (1998) Charge heterogeneity of macrophage migration inhibitory factor (MIF) in human liver and breast tissue. Electrophoresis. 19:2010–3.CrossRefGoogle Scholar
  27. 27.
    Watarai H, et al. (2000) Posttranslational modification of the glycosylation inhibiting factor (GIF) gene product generates bioactive GIF. Proc. Natl. Acad. Sci. U. S. A. 97:13251–6.CrossRefGoogle Scholar
  28. 28.
    Kim-Saijo M, Janssen EM, Sugie K. (2008) CD4 cell-secreted, posttranslationally modified cytokine GIF suppresses Th2 responses by inhibiting the initiation of IL-4 production. Proc. Natl. Acad. Sci. U. S. A. 105:19402–7.CrossRefGoogle Scholar
  29. 29.
    Leng L, et al. (2003) MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197:1467–76.CrossRefGoogle Scholar
  30. 30.
    Bucala R, Shachar I. (2014) The integral role of CD74 in antigen presentation, MIF signal transduction, and B cell survival and homeostasis. Mini. Rev. Med. Chem. 14:1132–8.CrossRefGoogle Scholar
  31. 31.
    Schwartz V, et al. (2009) A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett. 583:2749–57.CrossRefGoogle Scholar
  32. 32.
    Lue H, Dewor M, Leng L, Bucala R, Bernhagen J. (2011) Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell Signal. 23:135–44.CrossRefGoogle Scholar
  33. 33.
    Klasen C, et al. (2014) MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling. J. Immunol. 192:5273–84.CrossRefGoogle Scholar
  34. 34.
    Rex S, et al. (2014) The role of macrophage migration inhibitory factor in critical illness. Mini. Rev. Med. Chem. 14:1116–24.CrossRefGoogle Scholar
  35. 35.
    Asare Y, Schmitt M, Bernhagen J. (2013) The vascular biology of macrophage migration inhibitory factor (MIF): expression and effects in inflammation, atherogenesis and angiogenesis. Thromb. Haemost. 109:391–8.CrossRefGoogle Scholar
  36. 36.
    Yang Y, Sun M, Wang L, Jiao B. (2013) HIFs, angiogenesis, and cancer. J. Cell Biochem. 114:967–74.CrossRefGoogle Scholar
  37. 37.
    Koong AC, et al. (2000) Candidate genes for the hypoxic tumor phenotype. Cancer Res. 60:883–7.PubMedGoogle Scholar
  38. 38.
    Takahashi M, et al. (2001) Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes. Cardiovasc. Res. 52:438–45.CrossRefGoogle Scholar
  39. 39.
    Schmeisser A, et al. (2005) The expression of macrophage migration inhibitory factor 1alpha (MIF 1alpha) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability. Atherosclerosis. 178:83–94.CrossRefGoogle Scholar
  40. 40.
    Bacher M, et al. (2003) Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am. J. Pathol. 162:11–7.CrossRefGoogle Scholar
  41. 41.
    Baugh JA, et al. (2006) Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem. Biophys. Res. Commun. 347:895–903.CrossRefGoogle Scholar
  42. 42.
    Oda S, et al. (2008) Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner. PLoS One. 3:e2215.CrossRefGoogle Scholar
  43. 43.
    Han I, et al. (2008) Expression of macrophage migration inhibitory factor relates to survival in high-grade osteosarcoma. Clin. Orthop. Relat. Res. 466:2107–13.CrossRefGoogle Scholar
  44. 44.
    Hagemann T, et al. (2007) Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol. Cancer Ther. 6:1993–2002.CrossRefGoogle Scholar
  45. 45.
    Xu X, et al. (2007) Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett. 261:147–57.CrossRefGoogle Scholar
  46. 46.
    Ren Y, et al. (2005) Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann. Surg. 242:55–63.CrossRefGoogle Scholar
  47. 47.
    Shun CT, Lin JT, Huang SP, Lin MT, Wu MS. (2005) Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas. World J. Gastroenterol. 11:3767–71.CrossRefGoogle Scholar
  48. 48.
    Hira E, et al. (2005) Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer. 103:588–98.CrossRefGoogle Scholar
  49. 49.
    White ES, et al. (2003) Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin. Cancer Res. 9:853–60.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Wilson JM, et al. (2005) Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology. 129:1485–503.CrossRefGoogle Scholar
  51. 51.
    Martin J, et al. (2008) Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB)-induced nonmelanoma skin cancer (NMSC). FASEB J. 23:720–30.CrossRefGoogle Scholar
  52. 52.
    Schoenfeld J, et al. (2010) Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 70:10150–60.CrossRefGoogle Scholar
  53. 53.
    Choudhary S, et al. (2013) Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis. Carcinogenesis. 34:2891–9.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  1. 1.Molecular Targets Program, JG Brown Cancer Center, and the Department of MedicineUniversity of LouisvilleLouisvilleUSA

Personalised recommendations